Navigation Links
Singulex Collaborates With Large Pharmaceutical Company in Erenna(TM) Technology Access Program
Date:3/6/2008

Opens Facility to Support European Partnerships

ALAMEDA, Calif., and PARIS, March 6 /PRNewswire/ -- Singulex Inc. announced today a collaboration with Novartis Pharma AG to give Novartis access to Singulex's advanced biomarker detection technology through an Erenna(TM) Technology Access Program (ETAP). Terms of the collaboration were not disclosed. In addition, the company announced the opening of a facility in Paris, France to support the needs of Singulex's collaborators in Europe.

"We have gained tremendous traction with potential pharmaceutical partners in the last year," said Philippe Goix, Ph.D., president and CEO of Singulex. "Establishing this relationship with Novartis further validates the power of our technology in therapeutic efficacy and toxicity programs."

As part of its ETAP partnership with Novartis, Singulex has placed its flagship biomarker detection platform, the Erenna system, at Novartis' Basel, Switzerland facility and will be working with Novartis to develop biomarker assays that have the potential to advance Novartis' drug development programs. Erenna and accompanying assays are designed to measure very low levels and small changes of protein biomarkers across a variety of biological samples from multiple species.

"Among our goals is the establishment of strong collaborations with pharmaceutical companies that will bring advanced technologies to their translational medicine and biomarker programs," continued Goix. "By opening a facility in Europe, we are bringing our strong immunoassay development skills and Erenna technology closer to European partners. We are actively working to expand our footprint across the globe, and this facility does just that."

About Singulex

Singulex develops and commercializes innovative technology solutions that enable disease understanding and management for life science researchers and clinicians. Utilizing proprietary quantitative single molecule detection technology, Singulex develops customized biomarker diagnostic systems that can detect and quantify normal and abnormal protein biomarkers in a variety of biological samples with extreme sensitivity and accuracy. Singulex is currently conducting several pilot studies with academic and molecular diagnostic partners to validate the company's commercial digital molecule detection platform, the Erenna(TM) Immunoassay System. Singulex's research and development facilities are located at the Center for Emerging Technologies in St Louis, Missouri, and the company's commercial operations are based in Alameda, California. To learn more about Singulex, please visit us at http://www.singulex.com.

About ETAP

The Erenna(TM) Technology Access Program (ETAP) offers select clients the opportunity to use Singulex's flagship Erenna system to improve and validate their vital immunoassays, adding as much as 1-3 logs of improvement in sensitivity and providing less than 20% coefficient of variability. ETAP includes the Erenna system, which is designed to detect and count single molecules, customized immunoassay development services, reagents, software and direct and personal client service.


'/>"/>
SOURCE Singulex Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
2. GeneGo Collaborates With The Netherlands Toxicogenomics Center on $100 Million Grant
3. NIH collaborates with EPA to improve the safety testing of chemicals
4. Pathway Medical Technologies Adds Joe Rafferty as VP, Sales, and Moves To Larger Facility to Accommodate Rapid Growth
5. Safety Profile of TAXUS(R) Liberte(TM) Stent System Highlighted in Worlds Largest Stent Registry
6. Largest Asian Cancer Hospital to Evaluate New CT Laser Breast Imaging System
7. New technique producing small things in large quantities
8. A Large-Scale Research Project by a Dutch Consortium Addressing a Global Problem
9. Elbit Medical Imaging Ltd. Announces Definitive Agreements for a Large Scale Luxury Mixed Use Project in Bangalore, India
10. Researchers outline structure of largest nonvirus particle ever crystallized
11. China-Biotics, Inc. Receives Approval to Begin Construction on Large-Scale Manufacturing Facility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... Portland, OR (PRWEB) , ... ... ... , an industry-leading Unified Communications (UC) and Collaboration company, and Bigleaf Networks, ... announced today a strategic alliance to extend CallTower’s Unified Communication applications with ...
(Date:9/22/2017)... ... September 22, 2017 , ... ... nearly $200,000 via Kickstarter. The proceeds will be used to fund production of ... exceeding the original Kickstarter goal by nearly 1,000%. , The B2v2 is the ...
(Date:9/22/2017)... ... 22, 2017 , ... The Academy of Model Aeronautics (AMA) ... 29, 2017, to promote AMA’s programs, member services, and the model aviation hobby. ... but not limited to model aviation and other RC activities. , Thousands are ...
(Date:9/21/2017)... ... 21, 2017 , ... Dr. Greg Leyer, Chief Scientific Officer of UAS Labs, ... presentation is at 12:10pm in the Probiotics Resource Center, Mandalay Bay Expo Hall. ... discuss how probiotics have shown impressive data in areas outside the gut including heart ...
Breaking Biology Technology:
(Date:4/5/2017)... , April 4, 2017 KEY FINDINGS ... anticipated to expand at a CAGR of 25.76% during ... diseases is the primary factor for the growth of ... report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The global ... product, technology, application, and geography. The stem cell market ...
(Date:3/30/2017)... Trends, opportunities and forecast in this market ... (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, vein ... use industry (government and law enforcement, commercial and retail, ... others), and by region ( North America ... Pacific , and the Rest of the World) ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access System ... over the next decade to reach approximately $1,580 million by 2025. ... forecasts for all the given segments on global as well as ...
Breaking Biology News(10 mins):